Trials / Not Yet Recruiting
Not Yet RecruitingNCT06791824
Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
A Phase IB/II Clinical Study to Assess the Safety, Tolerability and Preliminary Efficacy of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 125 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety, tolerability and preliminary efficacy of CM313(SC) injection in patients with relapsed/refractory aplastic anemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM313(SC) injection | Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results. |
| BIOLOGICAL | CM313(SC) injection | Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results. |
| BIOLOGICAL | CM313(SC) injection | Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-01-24
- Last updated
- 2025-02-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06791824. Inclusion in this directory is not an endorsement.